On April 22nd, A-share listed company Beilu Pharmaceutical (300016) (300016) released its annual performance report for 2023. Of which, the net loss is 7175.Threecardpokerpayouts71 million yuan, stopping profits and turning losses.

According to the comprehensive operation and follow-up analysis of more than 1200 financial indicators of its financial data in the current period and the past five years, according to the financial diagnosis model of flush (300033), the overall financial situation of Beilu Pharmaceutical Industry in the past five years is lower than the industry average. Specifically, solvency, operating capacity and cash flow are general.

Net loss of 7175Threecardpokerpayouts.71 million yuan, stopping profits and turning losses

In terms of revenue and profit, the company achieved operating income of 891 million yuan this year, an increase of 16.30% over the same period last year, with a net loss of 71.7571 million yuan, and a net profit of 11.2839 million yuan in the same period last year, and basic earnings per share of-0.15 yuan.

In terms of assets, during the reporting period, the total assets at the end of the period were 2.819 billion yuan and the accounts receivable were 185 million yuan.ThreecardpokerpayoutsIn terms of cash flow, the net cash flow generated by business activities was 58.4608 million yuan, and the cash received from the sale of goods and services was 886 million yuan.

There are two financial highlights.

According to the relevant financial information released by Beilu Pharmaceutical Co., Ltd., the company has two financial highlights, as followsThreecardpokerpayouts:

The average year-on-year growth rate of revenue is 5.70%, which is excellent in the industry. The quick debt repayment ratio is 2.65, and the short-term solvency is excellent.

There are two financial risks

According to the relevant financial information released by Beilu Pharmaceutical Co., Ltd., the company has two financial risks, as follows:

The average year-on-year growth rate of operating profit is-194.39%, and the growth of the company is poor. The average turnover rate of inventory is 1.75 (times / year), and the ability to realize inventory is poor.

Overall, the overall financial situation of Beilu Pharmaceutical Industry is lower than the industry average, with a current total score of 1.10, ranking low among 157 companies in its chemical pharmaceutical industry. Specifically, solvency, operating capacity and cash flow are general.

The scores of the indicators are as follows:

Index type previous period score ranking evaluation of solvency 2.451.82101 general operating capacity 0.671.66106 general cash flow 4.681.34116 general growth capacity 0.250.41145 weaker profitability 0.610.38146 lower asset quality 1.662.5578 the total score is 1.251.10136 lower than the industry average

On the large model of financial diagnosis of flush

Flush (300033) Financial diagnosis model calculates the company's financial scores, highlights and risks based on the company's latest and previous financial data and industry conditions, reflecting the company's disclosed financial position, but not a forecast of the future financial position. The financial score range is 0-5. The higher the score, the better the financial situation and the greater the value of the medium-and long-term investment. In the financial highlights and risk reviews, the five-year average of the indicators related to the "average" keyword, and the latest reporting period data without the "average" keyword. All the above information is based on artificial intelligence algorithm, for reference only, does not represent flush financial point of view, investors operate accordingly, at their own risk.

Learn more about the company's stock diagnostic information >